scispace - formally typeset
J

Juan Angel Jover

Researcher at Hospital Clínico San Carlos

Publications -  109
Citations -  3840

Juan Angel Jover is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Population & Outpatient clinic. The author has an hindex of 27, co-authored 109 publications receiving 3406 citations. Previous affiliations of Juan Angel Jover include Hospital for Special Surgery & Complutense University of Madrid.

Papers
More filters
Journal ArticleDOI

Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

Alfred Mahr, +6 more
- 01 Aug 2007 - 
TL;DR: It is indicated that MTX could be considered as a therapeutic option in addition to standard-of-care treatment with corticosteroids for patients with GCA, and adjunctive treatment with MTX lowers the risk of relapse and reduces exposure to cortiosteroids.
Journal ArticleDOI

Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone: A Randomized, Double-Blind, Placebo-Controlled Trial

Juan Angel Jover, +5 more
- 16 Jan 2001 - 
TL;DR: Patients with newly diagnosed active giant-cell arteritis were consecutively entered into a randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of methotrexate therapy combined with corticosteroids in this condition.
Journal Article

Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone

Juan Angel Jover, +5 more
- 16 Jan 2001 - 
TL;DR: Treatment with methotrexate plus corticosteroid is a safe alternative to corticostosteroid therapy alone in patients with giant-cell arteritis and is more effective in controlling disease.
Journal ArticleDOI

Costs and predictors of costs in rheumatoid arthritis: A prevalence-based study

Cristina Lajas, +7 more
- 15 Feb 2003 - 
TL;DR: The data show a remarkable economic impact of RA over society and link the costs of the disease to its consequences in terms of functional disability, work disability, and housework disability.
Journal ArticleDOI

Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.

José María Álvaro-Gracia, +12 more
- 01 Jan 2017 - 
TL;DR: The intravenous infusion of Cx611 was in general well tolerated, without evidence of dose-related toxicity at the dose range and time period studied, and a trend for clinical efficacy was observed.